GEN Exclusives

More »

GEN News Highlights

More »
Dec 21, 2006

GSK Continues Acquisition Spree with Praecis Pharmaceuticals

  • In GlaxoSmithKline’s (GSK) fourth acquisition of the 2006, the company has agreed to buy Praecis Pharmaceuticals for approximately $54.8 million. "Praecis has created novel therapeutic programs and innovative chemical-synthesis and screening technology that will complement our own discovery capabilities," says Allen Oliff, senior vp, molecular discovery research, GSK. 

    GSK will pay $5 per share, representing more than double the company’s previous closing price of $1.99. Praecis opened trading today at $4.88. The companies expect to close the deal in the first quarter of 2007.

    Earlier in December, the company offered $454 million for Domantis. It also closed its transaction to take over CNS for $566 million. In February, GSK reported that it would be taking over Pliva’s proprietary R&D arm for a total potential cash consideration of up to $50 million.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?